Malaria Vaccine (R21/Matrix-M)
Malaria
Phase 3WHO Recommended
Key Facts
About Novavax
Novavax is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. Its core technology platform combines recombinant nanoparticle antigens with its patented saponin-based Matrix-M™ adjuvant to stimulate robust immune responses. The company achieved a major milestone with the global authorization of its COVID-19 vaccine and is now advancing a diversified pipeline targeting respiratory viruses. Novavax's strategic direction involves expanding the utility of its platform, pursuing combination vaccines, and establishing its commercial presence.
View full company profileTherapeutic Areas
Other Malaria Drugs
| Drug | Company | Phase |
|---|---|---|
| Chloroquine Phosphate | Ipca Laboratories | Commercial |
| Anti-malarial Portfolio | Strides Pharma | Approved |
| STANDARD Q Malaria Pf/Pan Ag Test | SD BioSensor | Approved |
| Anti-malarial Portfolio (ACTs) | Bliss GVS Pharma | Approved |